CBD (cannabidiol): definition and the French rules in 2026

CBD is short for cannabidiol, a name built from "cannabis" and the suffix "-diol", which refers to the molecule's two hydroxyl (OH) groups. According to PubChem (CID 644019), its molecular formula is C21H30O2, the same as THC's, with a molar mass of 314.5 g/mol.

Hemp makes it in its trichomes, the tiny glands covering its flowers. A review by the pharmacologist Roger Pertwee records that CBD was first obtained from cannabis in 1940 by Roger Adams's team. Raphael Mechoulam's laboratory worked out its structure in 1963, a year before isolating Δ⁹-THC.

The plant does not make CBD directly: an enzyme converts its CBGA into CBDA, the acidic form, which heat then decarboxylates into CBD. See our pages about CBG, CBDA and cannabinoids.

CBD can also be made by synthesis, the French Ministry of Agriculture notes, and the EU novel food catalogue treats synthetic cannabinoids as novel foods. Among plants, as far as is known in 2026, no other plant produces it.

The cannabis high comes from THC activating the brain's CB1 receptor. CBD acts differently. A 2015 cell study describes it as a negative allosteric modulator of the CB1 receptor, meaning it binds to another site on the receptor and dampens the effect of the molecules that activate it.

This receptor belongs to the endocannabinoid system: according to Pertwee's review, CB1 receptors sit mainly on nerve terminals and CB2 receptors on immune cells. CBD has other targets too, and the summary of product characteristics of Epidyolex states that the precise mechanism by which this medicine acts on seizures in humans is unknown. See the differences between CBD and THC.

The label "non-psychoactive" is too simple. In its September 2026 note, MILDECA, the French interministerial mission against drugs and addictive behaviour, writes that CBD causes no dependence but has psychoactive effects because it acts on the "central nervous system". The accurate statement is that it does not get you high: see does CBD get you high?

Not in the legal sense. CBD is not classified as a narcotic in France, and the Court of Justice of the European Union held in 2020 that it is not a narcotic drug within the meaning of the 1961 Convention. On 2 December 2020, the UN Commission on Narcotic Drugs rejected a WHO recommendation on CBD preparations, some States arguing that CBD was not under international control. In 2022 the Conseil d'État found that it has no psychotropic properties; in 2026 MILDECA and the Ministry of Agriculture describe it as having psychoactive effects. According to the ANSM, a CBD product containing more than 0.30% THC, or a synthetic cannabinoid such as HHC, H4CBD or THCP, is classified as a narcotic. See is CBD a drug?

CBD comes from hemp or from chemical synthesis. MILDECA lists flowers, mostly smoked and impossible to tell apart by eye from THC-rich flowers, vaping liquids, cosmetics and foods (oils, capsules, sweets), the last of which are not authorised. See where CBD comes from and CBD flower.

In trade usage, a full-spectrum extract keeps the other cannabinoids, THC traces included, a broad-spectrum extract removes the THC, and an isolate is purified CBD (full spectrum or isolate, broad spectrum, 99% isolate). In the two dossiers on which EFSA gave its opinion in September 2026, the isolate, at 98% CBD or more, is made by ethanol extraction then crystallisation, and the extract, which contains 57 to 65% CBD, by supercritical CO2 extraction then distillation.

In a pharmacy, CBD to swallow is no more authorised than anywhere else, and Epidyolex is subject to restricted medical prescription. See CBD in pharmacies and, for a manufacturer's document, how to read a certificate of analysis.

In France, only one CBD-based medicine has received a marketing authorisation, according to MILDECA. Epidyolex, authorised in the EU on 19 September 2019, is prescribed from age 2, in addition to other medicines, for seizures associated with Lennox-Gastaut or Dravet syndrome, together with clobazam, and with tuberous sclerosis complex. See Epidyolex and what the trials measured.

No other CBD product may claim a therapeutic effect, on pain of criminal penalties, MILDECA points out. Medical cannabis falls under a different regime: according to the ANSM, the French medicines agency, enrolment ended on 27 March 2024, and patients still being treated remain covered until three months after the opinion of the Haute Autorité de santé. See medical cannabis, a separate framework.

Is it good to take? For the ANSM, using CBD, even a compliant product, "is not harmless". EFSA's provisional safe level, roughly 2 mg a day for a 70 kg adult, concerns supplements that are themselves not authorised and is in no way a recommended dose (that safe level explained).

The documented risks are drowsiness, possible effects on the liver, drug interactions and mislabelled products. In patients treated with Epidyolex, the medicine's summary reports drowsiness and sedation, which alcohol can increase, and dose-related rises in liver enzymes.

CBD is broken down in the liver, mainly by the enzymes CYP3A4 and CYP2C19, and it inhibits CYP2C19 in vitro. If you take any medicine, talk to your doctor or pharmacist (drug interactions, CBD and the liver).

The same summary also advises, as a precaution, avoiding cannabidiol during pregnancy and stopping breastfeeding. In March 2025, the French agency Anses proposed classifying CBD as presumed toxic for reproduction, category 1B, a classification that ECHA's Committee for Risk Assessment backed in March 2026, according to MILDECA (pregnancy and breastfeeding, the reproductive toxicity classification).

Since early 2024, the ANSM has recorded several hundred poisonings linked to products sold as CBD, most often because of THC above 0.30% or synthetic cannabinoids; a 2023 study found 8 products in 10 whose CBD content differed from the label. In a life-threatening emergency in France, call 15 or 112, or text 114 if you are deaf or hard of hearing; for other symptoms, a poison centre answers on 01 45 42 59 59 (synthetic cannabis, recalled batches, side effects of CBD).

Yes, with conditions: CBD is not a narcotic, but each type of product follows its own text.

According to the Ministry of Agriculture, foods containing CBD are not authorised under the novel food regulation, since their safety has not been demonstrated, and as of 10 August 2026 no cannabinoid appears on the Union list of authorised novel foods. Hemp seed oil, when not enriched, therefore has nothing to do with a CBD oil. See what is still on sale in 2026 and the permitted THC level. As for "French CBD", origin is not one of the legal conditions: see French CBD and its labels.

CBD's status took shape in stages, in Luxembourg, Paris, Parma and Brussels.

• 19 November 2020: the Kanavape ruling (C-663/18) of the Court of Justice of the European Union holds that CBD is not a narcotic drug within the meaning of the 1961 Convention.
• 30 December 2021: the hemp decree limits varieties and extracts to 0.30% Δ⁹-THC or less, and bans the sale of raw flowers.
• 29 December 2022: the Conseil d'État annuls that ban (no. 444887).
• 13 June 2023: the ANSM classifies HHC and two derivatives as narcotics.
• 3 June 2024: the ANSM extends the list to H4CBD, THCP and other derivatives.
• 26 March 2025: the Conseil d'État upholds the ban on selling plants and taking cuttings (no. 489210).
• 9 February 2026: EFSA publishes a provisional safe level of 0.0275 mg per kilo per day, roughly 2 mg for a 70 kg adult.
• 26 March 2026: the EU Scientific Committee on Consumer Safety (SCCS) considers CBD safe in cosmetics up to 0.19%, in a scientific opinion.
• 20 May 2026: the Ministry of Agriculture states that CBD foods are illegal and extends its checks to every one of them.
• 28 July 2026: Regulation (EU) 2026/1828 caps THC in hemp leaves for infusion from 1 January 2027.
• September 2026: EFSA finds a synthetic CBD safe under set conditions, and cannot conclude on two dossiers for hemp-derived CBD.

No general ban has been announced as of 20 October 2026, and the 2026 measures target products to swallow. In September 2026, EFSA found a synthetic CBD of at least 98% purity safe under the conditions of use proposed by the applicant (a supplement limited to 2 mg a day, intended for adults over 25 other than pregnant or breastfeeding women), except for people taking medication. For a hemp isolate and a hemp extract, it concluded that safety cannot be established, as the applicants did not answer its data requests. An EFSA opinion is not an authorisation: the Commission and the Member States decide.

Another possible change would come from classifying CBD as toxic for reproduction, which MILDECA expects to be adopted in early 2028, with an 18-month transition. CBD would then be banned in cosmetics, barring a derogation, and vaping liquids with 0.3% CBD or more could be banned too. See what is still on sale in 2026.

Roadside saliva tests look for THC, and a compliant CBD product can contain traces of it. On 21 June 2023 (no. 22-85.530), the French Court of Cassation ruled that the offence of driving after using narcotics is made out whatever the dose, even when the product was on open sale. In its version in force since 20 August 2026, article L235-1 of the Highway Code sets the penalty at three years in prison and a 9,000 euro fine, and the licence can be suspended for up to five years. The ANSM also advises road users against CBD. See CBD and driving.

Differences between countries are covered in the law around the world.

Texts re-read on 20 and 28 October 2026; the dates are those of publication or of the version in force.

• French law: decree of 30 December 2021; Conseil d'État, no. 444887 and no. 489210; Court of Cassation, no. 22-85.530; Highway Code, L235-1 (version of 20 August 2026); Public Health Code, L3421-1, L3513-5 and L3514-1.
• European Union: CJEU, C-663/18; Regulations 2015/2283 and 2026/1828; SCCS, SCCS/1685/25; EFSA, 9 February and September 2026.
• Agencies and international: MILDECA, "En matière de CBD"; French Ministry of Agriculture; ANSM; Anses; EMA; UN News; WADA; PubChem.
• Next review: the Haute Autorité de santé's opinion on medical cannabis, or a Commission decision on classifying CBD or on synthetic CBD.